219 related articles for article (PubMed ID: 22507895)
1. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.
Miller AC; Gelmanova IY; Keshavjee S; Atwood S; Yanova G; Mishustin S; Furin JJ; Shin SS
Int J Tuberc Lung Dis; 2012 Jul; 16(7):891-6. PubMed ID: 22507895
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome.
Keshavjee S; Gelmanova IY; Shin SS; Mishustin SP; Andreev YG; Atwood S; Furin JJ; Miller A
Int J Tuberc Lung Dis; 2012 May; 16(5):596-603. PubMed ID: 22410436
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.
Cavanaugh JS; Kazennyy BY; Nguyen ML; Kiryanova EV; Vitek E; Khorosheva TM; Nemtsova E; Cegielski JP
Int J Tuberc Lung Dis; 2012 Aug; 16(8):1069-74. PubMed ID: 22691694
[TBL] [Abstract][Full Text] [Related]
5. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
[TBL] [Abstract][Full Text] [Related]
8. Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India.
Duraisamy K; Mrithyunjayan S; Ghosh S; Nair SA; Balakrishnan S; Subramoniapillai J; Oeltmann JE; Moonan PK; Kumar AM
Ann Am Thorac Soc; 2014 Jun; 11(5):712-8. PubMed ID: 24735096
[TBL] [Abstract][Full Text] [Related]
9. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.
Bloss E; Kuksa L; Holtz TH; Riekstina V; Skripconoka V; Kammerer S; Leimane V
Int J Tuberc Lung Dis; 2010 Mar; 14(3):275-81. PubMed ID: 20132617
[TBL] [Abstract][Full Text] [Related]
10. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment.
Shin SS; Keshavjee S; Gelmanova IY; Atwood S; Franke MF; Mishustin SP; Strelis AK; Andreev YG; Pasechnikov AD; Barnashov A; Tonkel TP; Cohen T
Am J Respir Crit Care Med; 2010 Aug; 182(3):426-32. PubMed ID: 20413630
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
12. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-EchevarrÃa A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
[TBL] [Abstract][Full Text] [Related]
13. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
[TBL] [Abstract][Full Text] [Related]
14. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
[TBL] [Abstract][Full Text] [Related]
15. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
[TBL] [Abstract][Full Text] [Related]
16. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia.
Gelmanova IY; Ahmad Khan F; Becerra MC; Zemlyanaya NA; Unakova IA; Andreev YG; Berezina VI; Pavlova VE; Shin S; Yedilbayev AB; Krasnov VA; Keshavjee S
Int J Tuberc Lung Dis; 2015 Apr; 19(4):399-405. PubMed ID: 25859994
[TBL] [Abstract][Full Text] [Related]
17. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
[TBL] [Abstract][Full Text] [Related]
18. 'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters.
Gelmanova IY; Taran DV; Mishustin SP; Golubkov AA; Solovyova AV; Keshavjee S
Int J Tuberc Lung Dis; 2011 Oct; 15(10):1373-9. PubMed ID: 22283898
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda.
Ategyeka PM; Muhoozi M; Naturinda R; Kageni P; Namugenyi C; Kasolo A; Kisaka S; Kiwanuka N
BMC Infect Dis; 2023 Mar; 23(1):149. PubMed ID: 36899299
[TBL] [Abstract][Full Text] [Related]
20. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
